APA (7th ed.) Citation

Q, Z., T, H., Y, C., K, C., Y, O., X, D., . . . H, Y. (2026). Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. CNS neuroscience & therapeutics, 32(6), e70993. https://doi.org/10.1002/cns.70993

Chicago Style (17th ed.) Citation

Q, Zhou, He T, Cheng Y, Chen K, Ouyang Y, Dong X, Shi G, Wen Z, and Yang H. "Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation." CNS Neuroscience & Therapeutics 32, no. 6 (2026): e70993. https://doi.org/10.1002/cns.70993.

MLA (9th ed.) Citation

Q, Zhou, et al. "Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation." CNS Neuroscience & Therapeutics, vol. 32, no. 6, 2026, p. e70993, https://doi.org/10.1002/cns.70993.